Energy & environment · 19/10/2026

Lilly's Omvoh (mirikizumab-mrkz) Achieves Key Milestone in Pediatric Ulcerative Colitis Treatment

Lilly plans to submit clinical data to global regulators to support a potential label expansion for pediatric ulcerative colitis, following the successful completion of Phase 3 trials for its IL-23p19 inhibitor, Omvoh.